TW201841636A - 使用ccr3抑制劑治療視網膜相關疾病之方法及組合物 - Google Patents

Info

Publication number

TW201841636A

TW201841636A TW107112125A TW107112125A TW201841636A TW 201841636 A TW201841636 A TW 201841636A TW 107112125 A TW107112125 A TW 107112125A TW 107112125 A TW107112125 A TW 107112125A TW 201841636 A TW201841636 A TW 201841636A

Authority

TW

Taiwan

Prior art keywords

alkyl

group

optionally substituted

optionally

compound

Prior art date

2017-04-05

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 114
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 65
• 201000010099 disease Diseases 0.000 title claims abstract description 63
• 230000002207 retinal effect Effects 0.000 title claims abstract description 63
• 239000000203 mixture Substances 0.000 title claims description 84
• 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title abstract description 3
• 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title abstract 2
• 239000003112 inhibitor Substances 0.000 title description 25
• 230000004438 eyesight Effects 0.000 claims abstract description 33
• 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 23
• 201000005667 central retinal vein occlusion Diseases 0.000 claims abstract description 15
• 208000004644 retinal vein occlusion Diseases 0.000 claims abstract description 15
• 125000000217 alkyl group Chemical group 0.000 claims description 432
• 150000001875 compounds Chemical class 0.000 claims description 200
• 229910005965 SO 2 Inorganic materials 0.000 claims description 180
• -1 methoxy-phenyl Chemical group 0.000 claims description 171
• 229910052799 carbon Inorganic materials 0.000 claims description 155
• 229910052739 hydrogen Inorganic materials 0.000 claims description 113
• 150000003839 salts Chemical class 0.000 claims description 68
• 125000004432 carbon atom Chemical group C* 0.000 claims description 56
• 150000002367 halogens Chemical class 0.000 claims description 55
• 239000013078 crystal Substances 0.000 claims description 54
• 229910052736 halogen Inorganic materials 0.000 claims description 54
• 239000007937 lozenge Substances 0.000 claims description 54
• 239000000460 chlorine Substances 0.000 claims description 49
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 46
• 239000008194 pharmaceutical composition Substances 0.000 claims description 46
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 44
• 125000004076 pyridyl group Chemical group 0.000 claims description 44
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 43
• 229910052757 nitrogen Inorganic materials 0.000 claims description 43
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
• 229910052801 chlorine Inorganic materials 0.000 claims description 42
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 42
• 238000006467 substitution reaction Methods 0.000 claims description 42
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 38
• 229910052794 bromium Inorganic materials 0.000 claims description 33
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 32
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 32
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 32
• 150000001721 carbon Chemical group 0.000 claims description 31
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 31
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 31
• 229910052731 fluorine Inorganic materials 0.000 claims description 30
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 29
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 28
• 239000003085 diluting agent Substances 0.000 claims description 28
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 28
• 239000003814 drug Substances 0.000 claims description 27
• 125000001072 heteroaryl group Chemical group 0.000 claims description 26
• 125000000623 heterocyclic group Chemical group 0.000 claims description 26
• 229910052760 oxygen Inorganic materials 0.000 claims description 26
• 125000001113 thiadiazolyl group Chemical group 0.000 claims description 26
• 125000001188 haloalkyl group Chemical group 0.000 claims description 25
• 235000019359 magnesium stearate Nutrition 0.000 claims description 23
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 23
• 229910052717 sulfur Inorganic materials 0.000 claims description 23
• 125000000335 thiazolyl group Chemical group 0.000 claims description 23
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 22
• 125000003386 piperidinyl group Chemical group 0.000 claims description 21
• 125000001425 triazolyl group Chemical group 0.000 claims description 21
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 20
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 20
• 239000002253 acid Substances 0.000 claims description 19
• 125000002947 alkylene group Chemical group 0.000 claims description 19
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 19
• 125000000304 alkynyl group Chemical group 0.000 claims description 18
• 239000007884 disintegrant Substances 0.000 claims description 18
• 239000000314 lubricant Substances 0.000 claims description 18
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 17
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 17
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 17
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 17
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical class C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 17
• 125000003342 alkenyl group Chemical group 0.000 claims description 17
• 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 17
• 238000002560 therapeutic procedure Methods 0.000 claims description 17
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
• 125000002837 carbocyclic group Chemical group 0.000 claims description 16
• 125000002971 oxazolyl group Chemical group 0.000 claims description 16
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 16
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 16
• 239000002552 dosage form Substances 0.000 claims description 15
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 15
• QSOQBXCVRUTKSI-UHFFFAOYSA-N 4,5-dihydrobenzo[g][1,3]benzothiazole Chemical compound C1CC2=CC=CC=C2C2=C1N=CS2 QSOQBXCVRUTKSI-UHFFFAOYSA-N 0.000 claims description 14
• 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 14
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 14
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 14
• 239000003795 chemical substances by application Substances 0.000 claims description 14
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 14
• 125000001041 indolyl group Chemical group 0.000 claims description 14
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
• 150000001450 anions Chemical group 0.000 claims description 13
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 13
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
• 125000001424 substituent group Chemical group 0.000 claims description 13
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 13
• 239000004480 active ingredient Substances 0.000 claims description 12
• 125000003118 aryl group Chemical group 0.000 claims description 12
• 239000011230 binding agent Substances 0.000 claims description 12
• 235000010355 mannitol Nutrition 0.000 claims description 12
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 11
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 11
• 229930195725 Mannitol Natural products 0.000 claims description 11
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 11
• 239000002202 Polyethylene glycol Substances 0.000 claims description 11
• 125000002632 imidazolidinyl group Chemical group 0.000 claims description 11
• 239000000594 mannitol Substances 0.000 claims description 11
• 229920001223 polyethylene glycol Polymers 0.000 claims description 11
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 11
• 239000000454 talc Substances 0.000 claims description 11
• 229910052623 talc Inorganic materials 0.000 claims description 11
• 235000012222 talc Nutrition 0.000 claims description 11
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 10
• 229920002261 Corn starch Polymers 0.000 claims description 10
• UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 10
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 10
• 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 10
• 239000008120 corn starch Substances 0.000 claims description 10
• 229940069328 povidone Drugs 0.000 claims description 10
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 10
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 9
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 9
• 229910004013 NO 2 Inorganic materials 0.000 claims description 9
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 9
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 9
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 9
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 9
• 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 9
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
• 229940095064 tartrate Drugs 0.000 claims description 9
• 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 8
• 239000002775 capsule Substances 0.000 claims description 8
• 125000004122 cyclic group Chemical group 0.000 claims description 8
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 7
• 229920000881 Modified starch Polymers 0.000 claims description 7
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 7
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
• 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 7
• ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 6
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 6
• 150000001335 aliphatic alkanes Chemical group 0.000 claims description 6
• 125000002619 bicyclic group Chemical group 0.000 claims description 6
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
• 238000009501 film coating Methods 0.000 claims description 6
• 239000007888 film coating Substances 0.000 claims description 6
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
• 235000001968 nicotinic acid Nutrition 0.000 claims description 6
• 239000011664 nicotinic acid Substances 0.000 claims description 6
• 239000000049 pigment Substances 0.000 claims description 6
• 125000001272 (C1-C4)-alkylene-phenyl group Chemical group 0.000 claims description 5
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 5
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 5
• 239000000872 buffer Substances 0.000 claims description 5
• 229960000913 crospovidone Drugs 0.000 claims description 5
• 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 5
• 208000011325 dry age related macular degeneration Diseases 0.000 claims description 5
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
• 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
• 229960003512 nicotinic acid Drugs 0.000 claims description 5
• 230000003287 optical effect Effects 0.000 claims description 5
• 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
• 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
• 239000004408 titanium dioxide Substances 0.000 claims description 5
• 125000000391 vinyl group Chemical class [H]C([*])=C([H])[H] 0.000 claims description 5
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
• 229930182821 L-proline Natural products 0.000 claims description 4
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
• 229910019142 PO4 Inorganic materials 0.000 claims description 4
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
• DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 4
• 229920001531 copovidone Polymers 0.000 claims description 4
• KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 4
• IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims description 4
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical group OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 4
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 4
• 239000010452 phosphate Substances 0.000 claims description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
• 229960002429 proline Drugs 0.000 claims description 4
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
• 239000012748 slip agent Substances 0.000 claims description 4
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 4
• 229920002554 vinyl polymer Chemical class 0.000 claims description 4
• OCQAXYHNMWVLRH-UHFFFAOYSA-N 2,3-dibenzoyl-2,3-dihydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(O)(C(O)=O)C(O)(C(=O)O)C(=O)C1=CC=CC=C1 OCQAXYHNMWVLRH-UHFFFAOYSA-N 0.000 claims description 3
• CIWBSHSKHKDKBQ-SZSCBOSDSA-N 2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound OC[C@H](O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-SZSCBOSDSA-N 0.000 claims description 3
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
• 235000019766 L-Lysine Nutrition 0.000 claims description 3
• 239000002211 L-ascorbic acid Substances 0.000 claims description 3
• 235000000069 L-ascorbic acid Nutrition 0.000 claims description 3
• 239000004472 Lysine Substances 0.000 claims description 3
• 229910002651 NO3 Inorganic materials 0.000 claims description 3
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
• 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
• 239000000853 adhesive Substances 0.000 claims description 3
• 230000001070 adhesive effect Effects 0.000 claims description 3
• 239000001273 butane Substances 0.000 claims description 3
• 229960005069 calcium Drugs 0.000 claims description 3
• 239000011575 calcium Substances 0.000 claims description 3
• 229910052791 calcium Inorganic materials 0.000 claims description 3
• 229910000389 calcium phosphate Inorganic materials 0.000 claims description 3
• VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 claims description 3
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
• OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 3
• 229960005141 piperazine Drugs 0.000 claims description 3
• 239000004014 plasticizer Substances 0.000 claims description 3
• 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
• 235000019204 saccharin Nutrition 0.000 claims description 3
• 229940081974 saccharin Drugs 0.000 claims description 3
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims description 3
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims description 3
• 229960001860 salicylate Drugs 0.000 claims description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
• 239000000811 xylitol Substances 0.000 claims description 3
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
• 235000010447 xylitol Nutrition 0.000 claims description 3
• 229960002675 xylitol Drugs 0.000 claims description 3
• BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 2
• 239000004380 Cholic acid Substances 0.000 claims description 2
• KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 2
• 229930182831 D-valine Natural products 0.000 claims description 2
• 239000004471 Glycine Substances 0.000 claims description 2
• ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 claims description 2
• SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 claims description 2
• 229940061587 calcium behenate Drugs 0.000 claims description 2
• YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 claims description 2
• 229940062672 calcium dihydrogen phosphate Drugs 0.000 claims description 2
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
• 235000013539 calcium stearate Nutrition 0.000 claims description 2
• 239000008116 calcium stearate Substances 0.000 claims description 2
• SMBKCSPGKDEPFO-UHFFFAOYSA-L calcium;docosanoate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCCCCCC([O-])=O SMBKCSPGKDEPFO-UHFFFAOYSA-L 0.000 claims description 2
• 239000004359 castor oil Substances 0.000 claims description 2
• 235000019438 castor oil Nutrition 0.000 claims description 2
• BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 2
• 235000019416 cholic acid Nutrition 0.000 claims description 2
• 229960002471 cholic acid Drugs 0.000 claims description 2
• 239000008119 colloidal silica Substances 0.000 claims description 2
• 229920001577 copolymer Polymers 0.000 claims description 2
• KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 2
• 229960003964 deoxycholic acid Drugs 0.000 claims description 2
• 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
• 239000000194 fatty acid Substances 0.000 claims description 2
• 229930195729 fatty acid Natural products 0.000 claims description 2
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
• 235000019691 monocalcium phosphate Nutrition 0.000 claims description 2
• 229960005010 orotic acid Drugs 0.000 claims description 2
• WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
• 229940035893 uracil Drugs 0.000 claims description 2
• LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 claims 2
• 238000000634 powder X-ray diffraction Methods 0.000 claims 2
• 230000005855 radiation Effects 0.000 claims 2
• ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims 1
• DQDKOANVADPVQR-UHFFFAOYSA-N 5-imino-3,4-dihydropyrrol-2-amine Chemical compound NC1=NC(=N)CC1 DQDKOANVADPVQR-UHFFFAOYSA-N 0.000 claims 1
• ODHCTXKNWHHXJC-GSVOUGTGSA-N 5-oxo-D-proline Chemical compound OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 claims 1
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 1
• SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 claims 1
• IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 150000004665 fatty acids Chemical class 0.000 claims 1
• SKCKOFZKJLZSFA-FSIIMWSLSA-N fucitol Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO SKCKOFZKJLZSFA-FSIIMWSLSA-N 0.000 claims 1
• CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
• 229960002715 nicotine Drugs 0.000 claims 1
• SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
• WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims 1
• 229930192474 thiophene Natural products 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 abstract description 37
• 206010064930 age-related macular degeneration Diseases 0.000 abstract description 34
• 208000017442 Retinal disease Diseases 0.000 abstract description 9
• 206010038923 Retinopathy Diseases 0.000 abstract description 7
• 230000000007 visual effect Effects 0.000 abstract description 7
• 230000002028 premature Effects 0.000 abstract description 5
• 230000001976 improved effect Effects 0.000 abstract description 3
• 238000011282 treatment Methods 0.000 description 37
• 210000001525 retina Anatomy 0.000 description 35
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 34
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 34
• 239000005557 antagonist Substances 0.000 description 30
• 239000013543 active substance Substances 0.000 description 28
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 25
• 210000004204 blood vessel Anatomy 0.000 description 24
• 238000009472 formulation Methods 0.000 description 24
• 239000000546 pharmaceutical excipient Substances 0.000 description 22
• 239000000243 solution Substances 0.000 description 18
• 239000000843 powder Substances 0.000 description 17
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
• 239000008187 granular material Substances 0.000 description 16
• 229940079593 drug Drugs 0.000 description 15
• 238000013534 fluorescein angiography Methods 0.000 description 15
• 239000004615 ingredient Substances 0.000 description 15
• 238000011160 research Methods 0.000 description 15
• 238000012360 testing method Methods 0.000 description 15
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 14
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 14
• 239000008101 lactose Substances 0.000 description 14
• 229960001375 lactose Drugs 0.000 description 14
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
• 238000002156 mixing Methods 0.000 description 13
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
• 238000012014 optical coherence tomography Methods 0.000 description 12
• 230000004393 visual impairment Effects 0.000 description 12
• NDZYPHLNJZSQJY-QNWVGRARSA-N 1-(5-acetyl-4-methyl-1,3-thiazol-2-yl)-3-[(1r,2s)-2-[[(3s)-3-[(4-fluorophenyl)methyl]piperidin-1-yl]methyl]cyclohexyl]urea Chemical compound CC1=C(C(=O)C)SC(NC(=O)N[C@H]2[C@@H](CCCC2)CN2C[C@H](CC=3C=CC(F)=CC=3)CCC2)=N1 NDZYPHLNJZSQJY-QNWVGRARSA-N 0.000 description 11
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
• 230000000694 effects Effects 0.000 description 11
• 230000006872 improvement Effects 0.000 description 11
• 238000002347 injection Methods 0.000 description 11
• 239000007924 injection Substances 0.000 description 11
• 239000002245 particle Substances 0.000 description 11
• 239000003380 propellant Substances 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 10
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
• 239000011248 coating agent Substances 0.000 description 10
• 238000000576 coating method Methods 0.000 description 10
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 10
• 239000008108 microcrystalline cellulose Substances 0.000 description 10
• 229940016286 microcrystalline cellulose Drugs 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• 230000004304 visual acuity Effects 0.000 description 10
• 101150004010 CXCR3 gene Proteins 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• 206010029113 Neovascularisation Diseases 0.000 description 9
• 206010038848 Retinal detachment Diseases 0.000 description 9
• 230000004377 improving vision Effects 0.000 description 9
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 9
• 208000024891 symptom Diseases 0.000 description 9
• 239000003826 tablet Substances 0.000 description 9
• 201000004569 Blindness Diseases 0.000 description 8
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
• 206010025421 Macule Diseases 0.000 description 8
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 210000004369 blood Anatomy 0.000 description 8
• 239000008280 blood Substances 0.000 description 8
• 210000004027 cell Anatomy 0.000 description 8
• 230000008859 change Effects 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 229920000728 polyester Polymers 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 7
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 7
• 108050000258 Prostaglandin D receptors Proteins 0.000 description 7
• 102100024218 Prostaglandin D2 receptor 2 Human genes 0.000 description 7
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 7
• 239000000443 aerosol Substances 0.000 description 7
• 239000011737 fluorine Substances 0.000 description 7
• 125000005842 heteroatom Chemical group 0.000 description 7
• YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 7
• 239000003755 preservative agent Substances 0.000 description 7
• 102000005962 receptors Human genes 0.000 description 7
• 108020003175 receptors Proteins 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 230000001225 therapeutic effect Effects 0.000 description 7
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
• 206010021143 Hypoxia Diseases 0.000 description 6
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
• 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 6
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
• 235000010323 ascorbic acid Nutrition 0.000 description 6
• 239000011668 ascorbic acid Substances 0.000 description 6
• 229960005070 ascorbic acid Drugs 0.000 description 6
• 239000000975 dye Substances 0.000 description 6
• 239000007789 gas Substances 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• 230000002911 mydriatic effect Effects 0.000 description 6
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 6
• 239000008107 starch Substances 0.000 description 6
• 235000019698 starch Nutrition 0.000 description 6
• 210000002301 subretinal fluid Anatomy 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
• 229920002785 Croscarmellose sodium Polymers 0.000 description 5
• 208000010412 Glaucoma Diseases 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• 229930064664 L-arginine Natural products 0.000 description 5
• 235000014852 L-arginine Nutrition 0.000 description 5
• 239000000654 additive Substances 0.000 description 5
• 108010081667 aflibercept Proteins 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 5
• 239000003246 corticosteroid Substances 0.000 description 5
• 229960001334 corticosteroids Drugs 0.000 description 5
• 229960001681 croscarmellose sodium Drugs 0.000 description 5
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 238000013461 design Methods 0.000 description 5
• 125000005843 halogen group Chemical group 0.000 description 5
• 239000010410 layer Substances 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 150000007522 mineralic acids Chemical class 0.000 description 5
• 230000000877 morphologic effect Effects 0.000 description 5
• 210000002569 neuron Anatomy 0.000 description 5
• 125000006574 non-aromatic ring group Chemical group 0.000 description 5
• 150000007524 organic acids Chemical class 0.000 description 5
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 5
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 5
• 229960003876 ranibizumab Drugs 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 239000012453 solvate Substances 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 210000001519 tissue Anatomy 0.000 description 5
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• 208000001344 Macular Edema Diseases 0.000 description 4
• 206010025415 Macular oedema Diseases 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
• KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
• 108091008605 VEGF receptors Proteins 0.000 description 4
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
• 230000002411 adverse Effects 0.000 description 4
• 239000003963 antioxidant agent Substances 0.000 description 4
• 235000006708 antioxidants Nutrition 0.000 description 4
• 125000004429 atom Chemical group 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 4
• 239000007963 capsule composition Substances 0.000 description 4
• 235000015165 citric acid Nutrition 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 229940000406 drug candidate Drugs 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• 125000006038 hexenyl group Chemical group 0.000 description 4
• 125000005980 hexynyl group Chemical group 0.000 description 4
• 150000004677 hydrates Chemical class 0.000 description 4
• 150000002430 hydrocarbons Chemical group 0.000 description 4
• 230000001146 hypoxic effect Effects 0.000 description 4
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
• 201000010230 macular retinal edema Diseases 0.000 description 4
• 238000007909 melt granulation Methods 0.000 description 4
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
• 239000002547 new drug Substances 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 108091008695 photoreceptors Proteins 0.000 description 4
• 230000000750 progressive effect Effects 0.000 description 4
• 210000001747 pupil Anatomy 0.000 description 4
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 229910052708 sodium Inorganic materials 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
• 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 3
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• 208000032843 Hemorrhage Diseases 0.000 description 3
• 101000980744 Homo sapiens C-C chemokine receptor type 3 Proteins 0.000 description 3
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 125000002015 acyclic group Chemical group 0.000 description 3
• 229960002833 aflibercept Drugs 0.000 description 3
• 150000001298 alcohols Chemical class 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 239000002870 angiogenesis inducing agent Substances 0.000 description 3
• 238000002583 angiography Methods 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 210000001775 bruch membrane Anatomy 0.000 description 3
• 229910000019 calcium carbonate Inorganic materials 0.000 description 3
• 239000008139 complexing agent Substances 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 230000003111 delayed effect Effects 0.000 description 3
• 239000003889 eye drop Substances 0.000 description 3
• 229940012356 eye drops Drugs 0.000 description 3
• 239000000796 flavoring agent Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 235000013355 food flavoring agent Nutrition 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 229940093915 gynecological organic acid Drugs 0.000 description 3
• 238000009474 hot melt extrusion Methods 0.000 description 3
• 239000012943 hotmelt Substances 0.000 description 3
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
• 238000003384 imaging method Methods 0.000 description 3
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 210000005036 nerve Anatomy 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
• 235000005985 organic acids Nutrition 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 3
• 125000005981 pentynyl group Chemical group 0.000 description 3
• 229940124531 pharmaceutical excipient Drugs 0.000 description 3
• 210000000608 photoreceptor cell Anatomy 0.000 description 3
• 229940068196 placebo Drugs 0.000 description 3
• 239000000902 placebo Substances 0.000 description 3
• 230000001023 pro-angiogenic effect Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 230000004264 retinal detachment Effects 0.000 description 3
• 230000004233 retinal vasculature Effects 0.000 description 3
• 150000003384 small molecules Chemical class 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 230000008961 swelling Effects 0.000 description 3
• 238000010998 test method Methods 0.000 description 3
• CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
• PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
• HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
• WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• 108091023037 Aptamer Proteins 0.000 description 2
• KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
• 108090000426 Caspase-1 Proteins 0.000 description 2
• 241000218645 Cedrus Species 0.000 description 2
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
• 108010082548 Chemokine CCL11 Proteins 0.000 description 2
• 102000004003 Chemokine CCL11 Human genes 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 208000008069 Geographic Atrophy Diseases 0.000 description 2
• 102000003964 Histone deacetylase Human genes 0.000 description 2
• 108090000353 Histone deacetylase Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 208000009857 Microaneurysm Diseases 0.000 description 2
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
• 208000006550 Mydriasis Diseases 0.000 description 2
• JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 229920001800 Shellac Polymers 0.000 description 2
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
• 235000021355 Stearic acid Nutrition 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
• 230000005856 abnormality Effects 0.000 description 2
• 239000008186 active pharmaceutical agent Substances 0.000 description 2
• 239000000808 adrenergic beta-agonist Substances 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 125000005037 alkyl phenyl group Chemical group 0.000 description 2
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 229960000686 benzalkonium chloride Drugs 0.000 description 2
• RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
• 230000003454 betamimetic effect Effects 0.000 description 2
• 229960000397 bevacizumab Drugs 0.000 description 2
• 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 210000001124 body fluid Anatomy 0.000 description 2
• 239000010839 body fluid Substances 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
• 238000002144 chemical decomposition reaction Methods 0.000 description 2
• 150000001805 chlorine compounds Chemical group 0.000 description 2
• 239000000812 cholinergic antagonist Substances 0.000 description 2
• 210000003161 choroid Anatomy 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 229940125782 compound 2 Drugs 0.000 description 2
• 238000007334 copolymerization reaction Methods 0.000 description 2
• 229940099112 cornstarch Drugs 0.000 description 2
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 230000010339 dilation Effects 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 238000007907 direct compression Methods 0.000 description 2
• 150000002016 disaccharides Chemical class 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 208000035475 disorder Diseases 0.000 description 2
• 238000004090 dissolution Methods 0.000 description 2
• 239000008298 dragée Substances 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 210000003979 eosinophil Anatomy 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 150000002148 esters Chemical class 0.000 description 2
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
• 230000005496 eutectics Effects 0.000 description 2
• 229940051306 eylea Drugs 0.000 description 2
• 235000019264 food flavour enhancer Nutrition 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• 239000012458 free base Substances 0.000 description 2
• 239000001530 fumaric acid Substances 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 239000000938 histamine H1 antagonist Substances 0.000 description 2
• 102000043445 human CCR3 Human genes 0.000 description 2
• XOAGCJPTMIRCMN-UHFFFAOYSA-N hydroxybenzyltartaric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC1=CC=CC=C1 XOAGCJPTMIRCMN-UHFFFAOYSA-N 0.000 description 2
• 230000007954 hypoxia Effects 0.000 description 2
• 239000005414 inactive ingredient Substances 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 229910052500 inorganic mineral Inorganic materials 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 229960001021 lactose monohydrate Drugs 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 229940076783 lucentis Drugs 0.000 description 2
• 229940092110 macugen Drugs 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• 239000011976 maleic acid Substances 0.000 description 2
• 230000010534 mechanism of action Effects 0.000 description 2
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 239000011707 mineral Substances 0.000 description 2
• 150000002772 monosaccharides Chemical class 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 230000004660 morphological change Effects 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
• 239000003002 pH adjusting agent Substances 0.000 description 2
• 239000005022 packaging material Substances 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 229940071643 prefilled syringe Drugs 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 2
• BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 2
• JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical compound N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 210000001210 retinal vessel Anatomy 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 239000004208 shellac Substances 0.000 description 2
• 235000013874 shellac Nutrition 0.000 description 2
• 229940113147 shellac Drugs 0.000 description 2
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 238000001694 spray drying Methods 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• 239000008117 stearic acid Substances 0.000 description 2
• 229960004274 stearic acid Drugs 0.000 description 2
• 229960002317 succinimide Drugs 0.000 description 2
• 238000009495 sugar coating Methods 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000000153 supplemental effect Effects 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000002344 surface layer Substances 0.000 description 2
• 239000011975 tartaric acid Substances 0.000 description 2
• 235000002906 tartaric acid Nutrition 0.000 description 2
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
• 235000010215 titanium dioxide Nutrition 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 239000002525 vasculotropin inhibitor Substances 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 229940088594 vitamin Drugs 0.000 description 2
• 229930003231 vitamin Natural products 0.000 description 2
• 235000013343 vitamin Nutrition 0.000 description 2
• 239000011782 vitamin Substances 0.000 description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
• VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
• PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
• 125000006019 1-methyl-1-propenyl group Chemical group 0.000 description 1
• 125000006017 1-propenyl group Chemical group 0.000 description 1
• 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
• LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
• HVTUHSABWJPWNK-UHFFFAOYSA-N 2-[2-chloro-5-[3-(5-chlorospiro[3h-1-benzofuran-2,4'-piperidine]-1'-yl)-2-hydroxypropoxy]-4-(methylcarbamoyl)phenoxy]-2-methylpropanoic acid Chemical compound CNC(=O)C1=CC(Cl)=C(OC(C)(C)C(O)=O)C=C1OCC(O)CN1CCC2(OC3=CC=C(Cl)C=C3C2)CC1 HVTUHSABWJPWNK-UHFFFAOYSA-N 0.000 description 1
• OOKSMYZBWRKRGU-UHFFFAOYSA-N 2-benzoyl-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)C(=O)C1=CC=CC=C1 OOKSMYZBWRKRGU-UHFFFAOYSA-N 0.000 description 1
• KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical group C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical group CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
• WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• HXHAJRMTJXHJJZ-UHFFFAOYSA-N 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-(4-pyrrolidin-1-ylbutylcarbamoylamino)-1,2-thiazole-4-carboxamide Chemical compound S1N=C(OCC=2C(=CC(Br)=CC=2F)F)C(C(=O)N)=C1NC(=O)NCCCCN1CCCC1 HXHAJRMTJXHJJZ-UHFFFAOYSA-N 0.000 description 1
• 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• DGHJKOUXAHNRAP-UHFFFAOYSA-N 4-methyloxadiazole Chemical group CC1=CON=N1 DGHJKOUXAHNRAP-UHFFFAOYSA-N 0.000 description 1
• 239000003406 5-lipoxygenase-activating protein inhibitor Substances 0.000 description 1
• FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
• PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 1
• 102000009346 Adenosine receptors Human genes 0.000 description 1
• 108050000203 Adenosine receptors Proteins 0.000 description 1
• 102100022455 Adrenocorticotropic hormone receptor Human genes 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• ZTHQBROSBNNGPU-UHFFFAOYSA-N Butyl hydrogen sulfate Chemical class CCCCOS(O)(=O)=O ZTHQBROSBNNGPU-UHFFFAOYSA-N 0.000 description 1
• 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
• 102100036305 C-C chemokine receptor type 8 Human genes 0.000 description 1
• 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 description 1
• 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
• 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 description 1
• 108010040471 CC Chemokines Proteins 0.000 description 1
• 102000001902 CC Chemokines Human genes 0.000 description 1
• 108091008927 CC chemokine receptors Proteins 0.000 description 1
• 102000005674 CCR Receptors Human genes 0.000 description 1
• 229940127597 CGRP antagonist Drugs 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 102100035904 Caspase-1 Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
• 239000004097 EU approved flavor enhancer Substances 0.000 description 1
• 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
• 108050009340 Endothelin Proteins 0.000 description 1
• 102000002045 Endothelin Human genes 0.000 description 1
• 102100023688 Eotaxin Human genes 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 239000004386 Erythritol Substances 0.000 description 1
• UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 102000027484 GABAA receptors Human genes 0.000 description 1
• 108091008681 GABAA receptors Proteins 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
• 229940119240 Histamine H4 receptor antagonist Drugs 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 1
• 101000678419 Homo sapiens Adrenocorticotropic hormone receptor Proteins 0.000 description 1
• 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
• 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 1
• 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
• 101000716063 Homo sapiens C-C chemokine receptor type 8 Proteins 0.000 description 1
• 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
• 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
• 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 description 1
• 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
• 101100236208 Homo sapiens LTB4R gene Proteins 0.000 description 1
• 101001017969 Homo sapiens Leukotriene B4 receptor 2 Proteins 0.000 description 1
• 101000978431 Homo sapiens Melanocortin receptor 3 Proteins 0.000 description 1
• 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 1
• 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 1
• 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
• 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
• 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
• 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
• 101000818546 Homo sapiens N-formyl peptide receptor 2 Proteins 0.000 description 1
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
• 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 108700036276 KH902 fusion Proteins 0.000 description 1
• 102100035792 Kininogen-1 Human genes 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• 102100022118 Leukotriene A-4 hydrolase Human genes 0.000 description 1
• 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 description 1
• 102100033375 Leukotriene B4 receptor 2 Human genes 0.000 description 1
• 102000003680 Leukotriene B4 receptors Human genes 0.000 description 1
• 108090000093 Leukotriene B4 receptors Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 108020002496 Lysophospholipase Proteins 0.000 description 1
• 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
• 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 208000002720 Malnutrition Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 102000030612 Melanocortin 5 receptor Human genes 0.000 description 1
• 108010088565 Melanocortin 5 receptor Proteins 0.000 description 1
• 108090000950 Melanocortin Receptors Proteins 0.000 description 1
• 102000004378 Melanocortin Receptors Human genes 0.000 description 1
• 102100023726 Melanocortin receptor 3 Human genes 0.000 description 1
• 102100023724 Melanocortin receptor 4 Human genes 0.000 description 1
• 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
• 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
• 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
• 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
• 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
• 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
• 239000004368 Modified starch Substances 0.000 description 1
• 101100382966 Mus musculus Ccr3 gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 102100021126 N-formyl peptide receptor 2 Human genes 0.000 description 1
• 102000003945 NF-kappa B Human genes 0.000 description 1
• 108010057466 NF-kappa B Proteins 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
• 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
• 208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
• 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
• 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
• 102000000536 PPAR gamma Human genes 0.000 description 1
• 108010016731 PPAR gamma Proteins 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 description 1
• 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
• 206010036590 Premature baby Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102100024212 Prostaglandin D2 receptor Human genes 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 101000980728 Rattus norvegicus C-C chemokine receptor type 3 Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 201000007527 Retinal artery occlusion Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 1
• 101100437750 Schizosaccharomyces pombe (strain 972 / ATCC 24843) blt1 gene Proteins 0.000 description 1
• 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 239000004147 Sorbitan trioleate Substances 0.000 description 1
• PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
• 208000035286 Spontaneous Remission Diseases 0.000 description 1
• 208000027073 Stargardt disease Diseases 0.000 description 1
• 229930182558 Sterol Natural products 0.000 description 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
• 206010047139 Vasoconstriction Diseases 0.000 description 1
• 206010058990 Venous occlusion Diseases 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010047531 Visual acuity reduced Diseases 0.000 description 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
• 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
• 229920002494 Zein Polymers 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229940072056 alginate Drugs 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 239000003513 alkali Substances 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
• AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 150000001409 amidines Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 238000011122 anti-angiogenic therapy Methods 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000003097 anti-respiratory effect Effects 0.000 description 1
• 230000002137 anti-vascular effect Effects 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• 229940092738 beeswax Drugs 0.000 description 1
• UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
• 239000012965 benzophenone Substances 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• PRYZSLKPMFOUNL-MHIBGBBJSA-N bevasiranib Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 PRYZSLKPMFOUNL-MHIBGBBJSA-N 0.000 description 1
• 229950006615 bevasiranib Drugs 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 230000036770 blood supply Effects 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 229950000025 brolucizumab Drugs 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• IAQRGUVFOMOMEM-UHFFFAOYSA-N but-2-ene Chemical compound CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 1
• 229960001292 cabozantinib Drugs 0.000 description 1
• 229960003563 calcium carbonate Drugs 0.000 description 1
• 230000009460 calcium influx Effects 0.000 description 1
• 229960001714 calcium phosphate Drugs 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 229940078456 calcium stearate Drugs 0.000 description 1
• MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 201000005849 central retinal artery occlusion Diseases 0.000 description 1
• 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
• NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 230000004456 color vision Effects 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 229950005748 conbercept Drugs 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 235000008504 concentrate Nutrition 0.000 description 1
• 239000007859 condensation product Substances 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000008602 contraction Effects 0.000 description 1
• 229940109248 cromoglycate Drugs 0.000 description 1
• IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
• 238000011461 current therapy Methods 0.000 description 1
• 229940109275 cyclamate Drugs 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• NISGSNTVMOOSJQ-UHFFFAOYSA-N cyclopentanamine Chemical compound NC1CCCC1 NISGSNTVMOOSJQ-UHFFFAOYSA-N 0.000 description 1
• 230000001120 cytoprotective effect Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 201000011190 diabetic macular edema Diseases 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
• PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical class [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
• MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229940052760 dopamine agonists Drugs 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 239000013583 drug formulation Substances 0.000 description 1
• 238000007908 dry granulation Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 239000002713 epithelial sodium channel blocking agent Substances 0.000 description 1
• 229940009714 erythritol Drugs 0.000 description 1
• UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
• 235000019414 erythritol Nutrition 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 150000002191 fatty alcohols Chemical class 0.000 description 1
• 230000001497 fibrovascular Effects 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000007941 film coated tablet Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000013020 final formulation Substances 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 229960003883 furosemide Drugs 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 229940114119 gentisate Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 229960005150 glycerol Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 150000008282 halocarbons Chemical class 0.000 description 1
• 239000007902 hard capsule Substances 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
• SELIRUAKCBWGGE-UHFFFAOYSA-N hexadecanoic acid;octadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SELIRUAKCBWGGE-UHFFFAOYSA-N 0.000 description 1
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
• 229920001903 high density polyethylene Polymers 0.000 description 1
• 229920006158 high molecular weight polymer Polymers 0.000 description 1
• 239000004700 high-density polyethylene Substances 0.000 description 1
• 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
• 239000003396 histamine H4 receptor antagonist Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 210000002287 horizontal cell Anatomy 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 239000004093 hydrolase inhibitor Substances 0.000 description 1
• 150000004679 hydroxides Chemical class 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 229960003943 hypromellose Drugs 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical group C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 239000001282 iso-butane Substances 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 125000000468 ketone group Chemical group 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 108010072713 leukotriene A4 hydrolase Proteins 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 229920005610 lignin Polymers 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 150000002635 lipoxin A4 derivatives Chemical class 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 230000001071 malnutrition Effects 0.000 description 1
• 235000000824 malnutrition Nutrition 0.000 description 1
• 229960001855 mannitol Drugs 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229940071648 metered dose inhaler Drugs 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 238000003801 milling Methods 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 230000003020 moisturizing effect Effects 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• WYVBISCFCHREDA-UHFFFAOYSA-N n-cycloheptyl-6,7-dimethoxy-2-(4-piperidin-1-ylpiperidin-1-yl)quinazolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NC(N2CCC(CC2)N2CCCCC2)=NC=1NC1CCCCCC1 WYVBISCFCHREDA-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000004766 neurogenesis Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 208000015380 nutritional deficiency disease Diseases 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229920005787 opaque polymer Polymers 0.000 description 1
• 210000001328 optic nerve Anatomy 0.000 description 1
• 239000008184 oral solid dosage form Substances 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 102000004164 orphan nuclear receptors Human genes 0.000 description 1
• 108090000629 orphan nuclear receptors Proteins 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960003407 pegaptanib Drugs 0.000 description 1
• JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
• 239000003209 petroleum derivative Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
• SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
• 229960001802 phenylephrine Drugs 0.000 description 1
• 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• 239000002570 phosphodiesterase III inhibitor Substances 0.000 description 1
• 239000002606 phosphodiesterase VII inhibitor Substances 0.000 description 1
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 230000000649 photocoagulation Effects 0.000 description 1
• 238000001782 photodegradation Methods 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 229940075930 picrate Drugs 0.000 description 1
• OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
• 229960000540 polacrilin potassium Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 229920002689 polyvinyl acetate Polymers 0.000 description 1
• 239000011118 polyvinyl acetate Substances 0.000 description 1
• 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
• 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
• 239000005033 polyvinylidene chloride Substances 0.000 description 1
• 239000013312 porous aromatic framework Substances 0.000 description 1
• WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 239000000651 prodrug Substances 0.000 description 1
• 229940002612 prodrug Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• 239000002510 pyrogen Substances 0.000 description 1
• 229940043131 pyroglutamate Drugs 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 239000002994 raw material Substances 0.000 description 1
• 238000001525 receptor binding assay Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000004263 retinal angiogenesis Effects 0.000 description 1
• 230000004256 retinal image Effects 0.000 description 1
• 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
• 239000003590 rho kinase inhibitor Substances 0.000 description 1
• 238000005096 rolling process Methods 0.000 description 1
• 108091008601 sVEGFR Proteins 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 235000019337 sorbitan trioleate Nutrition 0.000 description 1
• 229960000391 sorbitan trioleate Drugs 0.000 description 1
• 239000008347 soybean phospholipid Substances 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 235000003702 sterols Nutrition 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• 230000000475 sunscreen effect Effects 0.000 description 1
• 239000000516 sunscreening agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000009492 tablet coating Methods 0.000 description 1
• 239000002700 tablet coating Substances 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
• QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000004149 thio group Chemical group *S* 0.000 description 1
• 125000004001 thioalkyl group Chemical group 0.000 description 1
• 229940098465 tincture Drugs 0.000 description 1
• 229930003799 tocopherol Natural products 0.000 description 1
• 229960001295 tocopherol Drugs 0.000 description 1
• 235000010384 tocopherol Nutrition 0.000 description 1
• 239000011732 tocopherol Substances 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229940066528 trichloroacetate Drugs 0.000 description 1
• YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
• 230000005740 tumor formation Effects 0.000 description 1
• 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
• 235000012141 vanillin Nutrition 0.000 description 1
• FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
• 230000025033 vasoconstriction Effects 0.000 description 1
• 239000013598 vector Substances 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 229940045997 vitamin a Drugs 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 210000004127 vitreous body Anatomy 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000005550 wet granulation Methods 0.000 description 1
• 229940093612 zein Drugs 0.000 description 1
• 239000005019 zein Substances 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1